Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients

Purpose Dyslipidemia has been established as one of the most important modifiable risk factors for cardiovascular disease. Due to the higher prevalence of dyslipidemia in males, this study aimed to estimate the prevalence of dyslipidemia in Iranian urban men. Materials and Methods A screening program was conducted in 845 Iranian men 25 years of age and older in 2014. A health interview survey was conducted to evaluate the prevalence of self-reported dyslipidemia and to collect demographic data, as well as serum lipid profile screening by a reference laboratory. Lipoprotein levels was categorized based on the Adult Treatment Panel III criteria and the data were analyzed using the chi-square test and analysis of variance. Results The overall prevalence of dyslipidemia was 51.8%, and the prevalence of various forms of dyslipidemia was as follows: hypercholesterolemia (≥240 mg/dL), 11.4%; hyper-low-density lipoprotein cholesterol (≥160 mg/dL), 9.6%; hypertriglyceridemia (≥200 mg/dL), 25%; and hypo-high-density lipoprotein (HDL) cholesterol (<40 mg/dL), 34.3%. With the exception of hypo-HDL, all forms of dyslipidemia were significantly less common in men over 65 years of age (p<0.05). Conclusions The prevalence of hypo-HDL and hypertriglyceridemia was higher than expected in Iranian adult men, with half of men 25 years of age and older affected by at least one form of dyslipidemia. A large gap in primary and secondary care was observed, because nearly 80% of patients with dyslipidemia were unaware of their status. Urgent preventive programs and lifestyle changes are necessary to reduce the prevalence of cardiovascular risk factors.

[1]  C. Park,et al.  Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005 , 2012, Diabetes & metabolism journal.

[2]  B. Eshrati,et al.  Estimation of the regional burden of non-communicable diseases due to obesity and overweight in Markazi province, Iran, 2006-2007 , 2012, Journal of cardiovascular disease research.

[3]  A. Mohammadbeigi,et al.  Education-related Inequity in Access and Utilization of Oral Health Care in Iran , 2015, Journal of family medicine and primary care.

[4]  B. Eshrati,et al.  Socioeconomic inequity in health care utilization, Iran , 2013, Journal of epidemiology and global health.

[5]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[6]  G. Prasad,et al.  Prevalence of Dyslipidemia and Hypertension in Indian Type 2 Diabetic Patients with Metabolic Syndrome and its Clinical Significance , 2014, Osong public health and research perspectives.

[7]  G. Moneta Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004 , 2009 .

[8]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[9]  T. Ashavaid,et al.  Prevalence of dyslipidemia in young adult Indian population. , 2008, The Journal of the Association of Physicians of India.

[10]  F. Sharifi,et al.  High prevalence of low high-density lipoprotein cholesterol concentrations and other dyslipidemic phenotypes in an Iranian population. , 2008, Metabolic syndrome and related disorders.

[11]  A. Mohammadbeigi,et al.  Horizontal inequity in access to outpatient services among Shiraz City residents, Iran. , 2015, Journal of research in health sciences.

[12]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[13]  C. Erem,et al.  Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study , 2008, Endocrine.

[14]  R. Petrella,et al.  Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. , 2007, Clinical therapeutics.

[15]  R. Posadas-Sánchez,et al.  Lipid and lipoprotein profiles and prevalence of dyslipidemia in Mexican adolescents. , 2007, Metabolism: clinical and experimental.

[16]  A. Sadek,et al.  Prevalence of dyslipidemia and obesity among college students in Kuwait , 2010 .

[17]  M. Rizzo,et al.  Prevalence of dyslipidemia and associated risk factors in Turkish adults. , 2014, Journal of clinical lipidology.

[18]  B. Claussen,et al.  High prevalence of obesity, dyslipidemia and metabolic syndrome in a rural area in Pakistan , 2008 .

[19]  L. Naz,et al.  Ischemic stroke: prevalence of modifiable risk factors in male and female patients in Pakistan. , 2009, Pakistan journal of pharmaceutical sciences.

[20]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[21]  B. Eshrati,et al.  Determinants of Inequity in Health Care Services Utilization in Markazi Province of Iran , 2013, Iranian Red Crescent medical journal.

[22]  Hsing-Yi Chang,et al.  Prevalence of dyslipidemia and mean blood lipid values in Taiwan: results from the Nutrition and Health Survey in Taiwan (NAHSIT, 1993-1996). , 2002, The Chinese journal of physiology.

[23]  B. Eshrati,et al.  Decomposition of inequity determinants of healthcare utilization, Iran. , 2013, Public health.

[24]  H. Florez,et al.  Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. , 2005, Diabetes research and clinical practice.

[25]  Y. Khader,et al.  Prevalence of dyslipidemia and its associated factors among Jordanian adults. , 2010, Journal of clinical lipidology.